<SEC-DOCUMENT>0000950103-20-000800.txt : 20200323
<SEC-HEADER>0000950103-20-000800.hdr.sgml : 20200323
<ACCEPTANCE-DATETIME>20200117170418
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950103-20-000800
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AC Immune SA
		CENTRAL INDEX KEY:			0001651625
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
		BUSINESS PHONE:		41 21 345 91 21

	MAIL ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">EPFL Innovation Park- Bldg B</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">1015 Lausanne, Switzerland</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">January 17, 2020</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>Re:</B></TD><TD><B>AC Immune SA<BR>
</B>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Form 20-F for the Fiscal Year Ended December
31, 2018</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Filed April 19, 2019</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Form 6-K for the Quarterly Period Ended
June 30, 2019</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Filed August 14, 2019</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>File No. 001 - 37891</B></P>

<B></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.5in"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Ms. Ibolya Ignat</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Mr. Franklin Wyman</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">U.S. Securities and Exchange Commission</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Office of Life Sciences</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">100 F Street N.E.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Washington, D.C. 20549-4628</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Dear Ms. Ignat and Mr. Wyman,</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.5in">On behalf of AC Immune SA (the &ldquo;Company&rdquo;
or &ldquo;AC Immune&rdquo;), I am responding to the comment from the Staff (the &ldquo;Staff&rdquo;) of the Securities and Exchange
Commission (the &ldquo;Commission&rdquo;) in the Staff&rsquo;s letter dated January 6, 2020 relating to the Company&rsquo;s financial
statements and disclosure in the Company&rsquo;s Form 6-K dated August 14, 2019.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.5in">Set forth below are the Company&rsquo;s responses
to the Staff&rsquo;s comment. For convenience, the Staff&rsquo;s comment is repeated below in italics, followed by the Company&rsquo;s
response to the comment.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><U>Form 6-K dated August 14, 2019</U></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><U>Exhibit 99.1&nbsp;</U></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><U>Interim Condensed Financial Statements (unaudited)&nbsp;</U></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><U>Notes to Interim Condensed Financial Statements&nbsp;</U></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><U>3.1 Licensing and collaboration agreements, page 13 </U></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><I>Please revise your disclosure to include the significant judgments
underlying your conclusion that the</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><I>license granted to Lilly was distinct and represented a right-to-use,
as addressed in IFRS 15.123 and 125. In this regard, consider providing certain information on pages 2-5 of your response, as follows:</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><I>The
nature of the license granted to Lilly with regard to its ongoing development and future commercialization activities,</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><I>The
degree to which the Pre-clinical and Phase 1 development activities conducted by you &ldquo;do not represent integrated services
with the licensed IP&rdquo; to Lilly and the absence of any impact of your R&amp;D activities on the &quot;form or functionality
of the underlying IP&quot; licensed to Lilly,</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><I>The
purpose of Pre-clinical and Phase 1 development activities conducted by Lilly and the absence of any linkage between these activities
and your development activities, other than through the joint steering committee and</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><I>The
nature and frequency of the information-sharing process through the joint steering committee and how this process is expected
to impact the future development activities to be independently conducted by you and Lilly.</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B><U>Company response</U></B>:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The Company acknowledges the Staff&rsquo;s comment and notes
in response to this comment that it currently intends to include the disclosure substantially in the form set forth in Exhibit
A to this response letter in its upcoming annual report on Form 20-F for the fiscal year ended December 31, 2019 (but that this
disclosure remains subject to completion of the company&rsquo;s internal procedures to finalize its upcoming annual report on Form
20-F).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">To the extent you have any questions regarding the response contained
in this letter, please do not hesitate to contact me at +41 21 345 91 37 or joerg.hornstein@acimmune.com.
Thank you for your time and attention.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in; text-align: left">Very truly yours,</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in; text-align: left">/s/ Joerg Hornstein</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in; text-align: left">Joerg Hornstein</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in; text-align: left">Chief Financial Officer</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 2.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 2.75in">&nbsp;</P>

<P STYLE="font: italic 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in">Tau Morphomer Small Molecule &ndash; 2018 license
agreement with Eli Lilly and Company</P>

<P STYLE="font: italic 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">In December 2018, we entered into an exclusive,
worldwide licensing agreement with Eli Lilly and Company (&ldquo;Lilly&rdquo;) to research and develop Tau Morphomer small molecules
for the treatment of Alzheimer&rsquo;s disease and other neurodegenerative diseases. More specifically, this is an exclusive license
with the right to grant sublicenses, under the ACIU Patents, the ACIU Know-How, and ACIU&rsquo;s interests in the Joint Patents
and the Joint Know-How to Exploit the Licensed Compounds and Licensed Products The agreement became effective on January 23, 2019
when the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired. On September 19, 2019,
the Company and Lilly entered into an amendment to divide the first discretionary milestone payment under the agreement of CHF
60 million into two installments with the first CHF 30 million paid in Q3 2019 and the second CHF 30 million to be paid on or before
March 31, 2020 unless Lilly earlier terminates the agreement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">Per the terms of the agreement, the Company
received an initial upfront payment of CHF 80 million in February 2019 for the rights granted by the Company to Lilly. The Company
is conducting the development of ACI-3024, our lead candidate from our Tau Morphomer small molecules program through the completion
of Phase 1, which commenced in the first half of 2019. Lilly will lead and fund further clinical development and will retain global
commercialization rights for all indications, including Alzheimer&rsquo;s disease, Progressive Supranuclear Palsy and other neurodegenerative
diseases. As it relates to our lead compound, ACI-3024, Lilly will lead development after the completion of Phase 1 and retain
commercialization rights. As of December 31, 2019, Lilly is engaged in certain Pre-clinical activities of its own as defined in
the agreement, which are intended to provide further data in support of the Phase 2 clinical study design.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">Per the terms of the agreement, the Company
may become eligible to receive additional milestone payments totaling up to approximately CHF 840 million for clinical and regulatory
milestones and CHF 900 million upon achievement of certain commercial milestones. In addition to milestones, we will be eligible
to receive royalties on sales at a percentage rate ranging from the low-double digits to the mid-teens. The agreement will terminate
by the date of expiration of the last royalty term for the last licensed product. However, under the terms of the agreement, Lilly
may terminate the agreement at any time after March 31, 2020 by providing three months&rsquo; notice to us.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune assessed this arrangement in accordance
with IFRS 15 and concluded that Lilly is a customer. The Company identified the following significant performance obligations under
the contract: (i) a right-of-use license and (ii) research and development activities outlined in the development plan. Per the
agreement, the Company is responsible for the pre-clinical and Phase 1 activities, which the Company determined are distinct and
capable of being completed by Lilly or a third party. Pre-clinical activities for which AC Immune was responsible prior to their
completion in May 2019 included final manufacturing of materials for use in the Phase 1 and regulatory submission of the protocols.
For the current Phase 1, AC Immune is responsible for leading the study design, obtaining relevant regulatory agency approvals,
arranging necessary third party contracts, completing patient selection, ensuring patient treatment, following up with patients,
drafting the clinical study report development and other relevant clinical activities to ensure that the primary objective of the
study is completed. The Company used CMOs for certain of its pre-clinical activities and is currently using CROs to complete certain
Phase 1 activities.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s pre-clinical and Phase
1 activities do not represent integrated services with the licensed IP for which Lilly contracted. Lilly purchased a license to
the Company&rsquo;s Tau therapeutic small molecule program, which was delivered at commencement of the agreement and AC Immune&rsquo;s
pre-clinical and Phase 1 activities do not affect the form or functionality of this license. The Company&rsquo;s objective of the
current Phase 1 activity is to assess safety and tolerability and does not modify or customize the lead compound and the completion
of these pre-clinical and Phase 1 activities does not affect the licensed IP.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">Finally, per the agreement, each party has
three representatives in a joint steering committee (&ldquo;JSC&rdquo;); depending upon the agenda, additional field experts can
attend the JSC to provide the technical and scientific contribution required. The JSC meets on a regular basis depending on agreements
between the representatives. The JSC is responsible for (i) serving as the forum to discuss, review and approve certain activities
by reviewing and discussing the development progress and updates to make, (ii) discuss, review and approve all amendments to the
global development plan, (iii) periodically serve as forum to discuss and review commercialization of licensed products and (iv)
review and approve reports related to development costs among other activities. The JSC is intended to ensure that communication
between the parties remains consistent and that the development plan is both agreed to and progressing as intended.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">The valuation of each performance obligation
involves estimates and assumptions with revenue recognition timing to be determined either by delivery or the provision of services.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">The Company used the residual approach to
estimate the selling price for the right-of-use license and an expected cost plus margin approach for estimating the research and
development activities. The right-of-use license was delivered on the effective date. The research and development activities are
expected to be delivered over time as the services are performed. For these services, revenue will be recognized over time using
the input method, based on costs incurred to perform the services, since the level of costs incurred over time is thought to best
reflect the transfer of services to Lilly. The Company determined the value of the research and development activities to be CHF
6.9 million and deferred this balance from the effective date. As of December 31, 2019, the Company has recognized CHF XY million
in revenue, resulting in a deferred income (contract liability) balance of CHF XY million of which CHF XY million is classified
as non-current. The remaining CHF 73.1 million from the upfront payment was allocated to the right-of-use license and recognized
on the effective date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">At inception of the agreement, none of the
clinical, regulatory or commercial milestones had been included in the transaction price, as all milestone amounts were fully constrained.
As acknowledged in the amendment completed between the Company and Lilly in Q3 2019, the Company earned and received a CHF 30 million
milestone payment related to the right-of-use license for IP. The Company recognized contract revenues in Q3 2019 as there were
no further constraints related to this milestone. In assessing that future clinical, regulatory or commercial milestones are fully
constrained, the Company considered numerous factors to determine that these milestones are not highly probable to obtain, including
that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and
the licensee&rsquo;s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when
the related sales occur as they were determined to relate predominantly to the license granted to Lilly and therefore have also
been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period and as uncertain
events are resolved or other changes in circumstances occur.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ -@# 2(  A$! Q$!_\0
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M6I-M>H44451SA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
